- 12月31日までに大麻は再分類されるでしょうか？11¢11%
The DEA administrative process for moving botanical marijuana from Schedule I to Schedule III remains in a limited briefing phase following an October 22 order from Chief ALJ Derek Julius. That ruling admitted a September GAO report highlighting gaps in federal scheduling procedures but denied requests to reopen the June-July 2026 hearings for additional testimony. Optional briefs on the report’s weight are due by November 5, after which the stay lifts and the judge can issue a nonbinding recommendation. An April 2026 Attorney General order already placed state-licensed medical marijuana and FDA-approved products into Schedule III, with the DEA issuing initial federal registrations to over 900 dispensaries in seven states as the first implementation step. Broader rescheduling covering adult-use cannabis requires the full hearing record, agency decision, and potential further review, keeping near-term resolution unlikely.
ルール
米国麻薬取締局（https://www.dea.gov/drug-information/drug-scheduling）が2026年12月31日 23:59 ETまでにマリファナをスケジュールIから他のいずれかの区分へ引き下げる（または完全に規制対象から外す）場合、この市場は「はい」で決着します。それ以外の場合、この市場は「いいえ」で決着します。 この市場の判定における主な情報源は米国政府の公式情報ですが、信頼できる報道の総意も使用します。
機械翻訳です。解釈に相違がある場合は原文が優先されます。